Roscovitine (Seliciclib, CYC202): Selective CDK2 Inhibitor for Cancer Biology Research

Executive Summary: Roscovitine (Seliciclib, CYC202) is a highly selective inhibitor of cyclin-dependent kinases (CDKs), with IC₅₀ values of 0.1 µM for CDK2/cyclin E and 0.16 µM for CDK5/p35, enabling precise cell cycle modulation in research models (APExBIO product page). It arrests cells in late prophase by blocking the prophase/metaphase transition, validated in Xenopus oocytes, starfish oocytes, and sea urchin embryos. In vivo, Roscovitine significantly inhibits tumor growth in athymic nude mice. The compound is insoluble in water but dissolves efficiently in DMSO and ethanol, supporting flexible use in assay design. Roscovitine is recommended for research focused on cell cycle regulation, kinase signaling, and cancer biology (Moret et al., 2019).

Biological Rationale

Cyclin-dependent kinases (CDKs) are essential regulators of eukaryotic cell cycle progression and transcription. Dysregulation of CDK activity is implicated in tumorigenesis and uncontrolled proliferation (Moret et al., 2019). Roscovitine (Seliciclib, CYC202) selectively inhibits CDK2, CDK5, CDK7, and CDC2, providing a tool to dissect their distinct roles in cell cycle checkpoints. This selectivity enables researchers to model cell cycle arrest and study molecular phenotypes associated with mitotic control. Small-molecule CDK inhibitors like Roscovitine are central to libraries optimized for kinome coverage and chemical genetics (Moret et al., 2019). Focused compound collections, such as those curated by APExBIO, facilitate high-content screening and phenotypic assays in cancer biology.

Mechanism of Action of Roscovitine (Seliciclib, CYC202)

Roscovitine is an ATP-competitive inhibitor targeting the active site of several cyclin-dependent kinases. The compound exhibits the following IC₅₀ values under biochemical assay conditions:

• CDK2/cyclin E: 0.1 µM
• CDK5/p35: 0.16 µM
• CDK7/cyclin H: 0.49 µM
• CDC2/cyclin B: 0.65 µM
• ERK2: 14 µM (less selective)
• ERK1: 34 µM (less selective)

Roscovitine blocks the transition from prophase to metaphase, thereby arresting cells in late prophase. The effect is observed in diverse systems, including Xenopus oocytes and sea urchin embryos. The compound also influences apoptosis pathways by suppressing CDK-driven transcription and cell division programs. At higher concentrations, Roscovitine can inhibit ERK1/2, but with markedly lower potency compared to CDK inhibition. For a detailed mechanistic perspective, see this protocol guide, which this article extends by adding recent cheminformatics analysis and in vivo benchmarks.

Evidence & Benchmarks

• Roscovitine inhibits CDK2/cyclin E with an IC₅₀ of 0.1 µM under in vitro conditions (APExBIO).
• It produces robust cell cycle arrest in late prophase in Xenopus oocytes, as confirmed by microscopy-based phenotyping (Moret et al., 2019).
• In athymic nude mice bearing A4573 tumors, Roscovitine significantly reduces tumor volume versus controls (in vivo efficacy study, APExBIO).
• Solubility: Roscovitine is insoluble in water but dissolves in DMSO (≥17.72 mg/mL) and ethanol (≥53.5 mg/mL) at room temperature (APExBIO).
• Integration into focused kinase libraries (e.g., LSP-OptimalKinase) increases selectivity and coverage for kinome targets in systematic screens (Moret et al., 2019).
• Roscovitine's effects on ERK1 and ERK2 are observed only at significantly higher concentrations (IC₅₀s of 34 µM and 14 µM, respectively), indicating limited off-target action at standard research doses (APExBIO).
• The compound is included in mechanism-of-action libraries for dissecting gene function and drug repurposing studies (Moret et al., 2019).

Applications, Limits & Misconceptions

Roscovitine is widely used in cancer biology to study cell cycle checkpoints, CDK signaling, and apoptosis. It serves as a reference inhibitor in kinase-centric screening and mechanistic research. The compound is instrumental in chemical genetic workflows, particularly where precise CDK2 inhibition is required. For translational and immuno-oncology workflows, see this guide, which focuses on actionable protocols and emergent applications. This article adds quantitative IC₅₀ data and solubility parameters for experimental planning.

Common Pitfalls or Misconceptions

• Non-selective at high concentrations: Roscovitine can inhibit ERK1/2 and other kinases at micromolar concentrations (>10 µM), reducing target precision.
• Insolubility in aqueous buffers: The compound is not water-soluble, requiring DMSO or ethanol for stock preparation.
• Not a pan-CDK inhibitor: Roscovitine is selective for CDK2, CDK5, CDK7, and CDC2, with limited activity against other CDKs.
• Not suitable for long-term solution storage: Degradation may occur; prepare fresh stocks for each experiment and store powder at -20°C.
• Not a therapeutic drug: Roscovitine is for research use only; clinical utility remains investigational.

Workflow Integration & Parameters

For optimal results, dissolve Roscovitine in DMSO or ethanol, using warming and ultrasonic treatment as needed. Work at concentrations below 10 µM to maximize CDK selectivity. Store the solid at -20°C and avoid repeated freeze-thaw cycles. Integration into high-content screening or phenotypic assays requires careful control of vehicle concentration. See this workflow article for troubleshooting and assay design; this article updates it by adding solubility data and in vivo benchmarks.

Conclusion & Outlook

Roscovitine (Seliciclib, CYC202) remains a gold-standard selective CDK2 inhibitor for cancer biology research. It enables precise cell cycle arrest, mechanistic interrogation of kinase signaling, and robust in vivo efficacy modeling. Focused libraries and cheminformatics-guided selection, as described by Moret et al. (2019), reinforce its value as a core research reagent. For more information or to order the A1723 kit, visit the APExBIO product page.